Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Sponsors › Advances in Clinical Genomics Profiling › FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

May 06, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration on Wednesday approved capmatinib (Novartis' Tabrecta) for treatment of patients with metastatic non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. CDC Combined COVID-19/Influenza Test Gets FDA Emergency Use Authorization

  2. FDA Grants EUAs for PCR Coronavirus Tests, Nasal Swab Self-Collection Kit

  3. Beckman Coulter Receives Emergency Use Authorization for SARS-CoV-2 Antibody Test

  4. Centogene Gets Emergency Use Authorization for PCR-Based Coronavirus Test

  5. InBios International Gets Emergency Use Authorization for Second Coronavirus Antibody Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.